Alteration of haemostasis in non-metastatic gastric cancer

Dig Liver Dis. 2001 Oct;33(7):546-50. doi: 10.1016/s1590-8658(01)80105-5.

Abstract

Background: Cancer is one of the most common acquired causes of venous thromboembolism.

Aim: To evaluate haemostasis disorders in patients with non-metastatic gastric cancer.

Patients and methods: We studied 11 patients with non-metastatic gastric cancer (9 males and 2 females, median age 54 years) and 20 healthy subjects (15 males and 5 females, median age 48 years) control. We measured prothrombin time, activated partial thromboplastin time, coagulation time, clot lysis time, fibrinogen, clotting factors (II, VII, VIII, IX, X), C protein, S protein, AT III, activated protein C resistance, prothrombin 1+2 fragment, tissue plasminogen activator and D-Dimer in all subjects.

Results: Fibrinogen plasma levels were significantly higher in patients with non-metastatic gastric cancer than in control group (505+/-24 mg/dl vs 336+/-30 mg/dl, p<0.001). We also found a significant increase in prothrombin 1+2 fragment plasma concentration compared with controls (3.8+/-0.6 nM vs 0.83+/-0.09 nM, p<0.001). Plasma D-dimer levels were 20-fold higher in patients with non-metastatic gastric cancer compared with controls (9.57+/-0.4 ng/dl vs 0.4+/-0.05 ng/dl, p<0.001). Also tissue plasminogen activator was significantly higher in gastric cancer patients than in controls (20.8+/-2.32 ng/ml vs 9.1+/-1.37 ng/ml, p<0.01). Finally clot lysis time was significantly accelerated in gastric cancer patients compared with control subjects (81+/-37 min vs 233+/-74 min, p<0.01).

Conclusions: Patients with non-metastatic gastric cancer are at risk for thrombotic events due to the combined increase in fibrinogen plasma levels and thrombin formation.

MeSH terms

  • Activated Protein C Resistance
  • Case-Control Studies
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinogen / analysis*
  • Fibrinolysis
  • Hemostasis / physiology
  • Humans
  • Male
  • Middle Aged
  • Partial Thromboplastin Time
  • Prothrombin Time
  • Stomach Neoplasms / blood*
  • Stomach Neoplasms / complications
  • Thrombin / analysis*
  • Thromboembolism / blood*
  • Thromboembolism / etiology
  • Tissue Plasminogen Activator / analysis

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Fibrinogen
  • Thrombin
  • Tissue Plasminogen Activator